Article Information
History
- March 16, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Anne Camille La Flamme, PhD1,2,*,
- David Abernethy, FRACP3,
- Dalice Sim, PhD4,
- Liz Goode, BN3,
- Michelle Lockhart, PhD5,
- David Bourke, FRACP3,
- Imogen Milner, RN3,
- Toni-Marie Garrill3,
- Purwa Joshi, FRACP3,
- Eloise Watson, RACP3,
- Duncan Smyth, FRACP3,
- Sean Lance, RACP3 and
- Bronwen Connor, PhD6
- 1School of Biological Sciences, Victoria University of Wellington, Wellington New Zealand
- 2Malaghan Institute of Medical Research, Wellington, New Zealand
- 3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
- 4Biostatistical Consulting Group, University of Otago, Wellington, New Zealand
- 5Pharmaceuticol Ltd, Auckland, New Zealand
- 6Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
- ↵*Corresponding author: Prof Anne Camille La Flamme, School of Biological Sciences, Victoria University of Wellington, P.O. Box 600, Wellington, 6140 New Zealand +64-4-463-6093 (office) anne.laflamme{at}vuw.ac.nz (e-mail)
Posted March 16, 2020.
Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase 1, randomized, blinded, placebo-controlled trial
